Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7017 - 7024 of 12091 results
SCOTUS Sets a Clock on Disgorgement in SEC Enforcement Actions
June 7, 2017| Blog| Viewpoint
NAIC Insurance Summit 2017: Innovation and Disruption Are Top of Mind for State Regulators
June 7, 2017| Advisory| Viewpoint
Mintz Benefits Attorney Patricia Moran Discusses Possible Changes to Obamacare Contraception Mandate
June 6, 2017| Blog| Viewpoint
I-94 Website Feature – CBP Now to Remind Travelers of Departure Date
June 6, 2017| Alert| Viewpoint
Healthcare Weekly Preview from ML Strategies - Week of June 5, 2017
June 6, 2017| Blog| Viewpoint
The Latest in the Epipen Medicaid Drug Rebate Saga – Where Are We Now?
June 6, 2017| Blog| Viewpoint
Second Circuit Orders En Banc Review of Panel Holding that Title VII Does Not Prohibit Sexual Orientation Discrimination
June 5, 2017| Blog| Viewpoint
Congress Returns for June Session to Face AHCA, User Fees and More
June 5, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|